Literature DB >> 7211316

Chordoma. A clinicopathologic and prognostic study of a Swedish national series.

B Eriksson, B Gunterberg, L G Kindblom.   

Abstract

Chordoma is a rare tumor with slow growth developing from remnants of the notochord and thus appears in close relation to the axial skeleton. A Swedish national series collected over a period of 13 years, comprising 51 patients with a follow-up time of 8-20 years, was studied. Histologically all tumors had a typical appearance except two, which had characteristics of "chondroid chordoma". Fifty-seven per cent of the tumors were located in the sacrococcygeal region, 27 per cent in the spheno-occipital region and 16 per cent in the vertebrae. The peak age incidence was in the 6th and 7th decades. Male: female ratio was 1:1. The main symptoms were pain and neurologic disturbances. Skeletal destruction was noted radiographically in most instances. Intratumoral calcifications were rarely seen. The treatment was surgery, radiotherapy or a combination of these. There was only one long-term survivor without evidence of disease, a patient operated on for cervical chordoma 14 years earlier. Six other patients lived 8-18 years after diagnosis with chordoma. All other patients were dead; 39 died of chordoma, five of unrelated causes. Distant metastases were noted in 29 per cent. Chordoma constituted 17.5 per cent of all primary malignant bone tumors of the axial skeleton. The yearly incidence was 0.51 per million inhabitants in Sweden.

Entities:  

Mesh:

Year:  1981        PMID: 7211316     DOI: 10.3109/17453678108991758

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  38 in total

Review 1.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

2.  Surgery for chordomas of the craniocervical junction: lessons learned.

Authors:  David Choi; Michael Gleeson
Journal:  Skull Base       Date:  2010-01

3.  Clivus chordoma: a report of 12 recent cases and review of the literature.

Authors:  J W Harbour; M T Lawton; G R Criscuolo; M J Holliday; D E Mattox; D M Long
Journal:  Skull Base Surg       Date:  1991

Review 4.  Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients.

Authors:  Muneyoshi Yasuda; Damien Bresson; Salvatore Chibbaro; Jan F Cornelius; Marc Polivka; Loic Feuvret; Masakazu Takayasu; Bernard George
Journal:  Neurosurg Rev       Date:  2011-08-24       Impact factor: 3.042

5.  Chondroid chordoma of the base of the skull: orbital and other neuro-ophthalmological symptoms.

Authors:  L A Bastiaensen; A C Leyten; T G Tjan; J F Misere
Journal:  Doc Ophthalmol       Date:  1983-02-28       Impact factor: 2.379

6.  Case report 205. Chordoma of mid-cervical spine.

Authors:  D J Stoker; J Pringle
Journal:  Skeletal Radiol       Date:  1982       Impact factor: 2.199

7.  Skull base chordoma with cavernous sinus involvement. Partial or radical tumour-removal?

Authors:  H Arnold; H D Herrmann
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

8.  Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.

Authors:  Yongkun Yang; Xiaohui Niu; Yuan Li; Weifeng Liu; Hairong Xu
Journal:  Eur Spine J       Date:  2016-12-09       Impact factor: 3.134

9.  Sacral chordoma: can local recurrence after sacrectomy be predicted?

Authors:  S A Hanna; W J S Aston; T W R Briggs; S R Cannon; A Saifuddin
Journal:  Clin Orthop Relat Res       Date:  2008-06-27       Impact factor: 4.176

Review 10.  Pediatric cervical chordoma: report of two cases and a review of the current literature.

Authors:  Gwi Hyun Choi; Moon-Sool Yang; Do Heum Yoon; Hyun Chyul Shin; Keung Nyun Kim; Seong Yi; Dong Yeop Lee; Poong Gi Ahn; Yoon Ha
Journal:  Childs Nerv Syst       Date:  2010-01-22       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.